Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town 7700, South Africa.
School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa.
Molecules. 2023 May 23;28(11):4276. doi: 10.3390/molecules28114276.
Novel antitubercular compounds are urgently needed to combat drug-resistant (Mtb). Filamentous actinobacteria have historically been an excellent source of antitubercular drugs. Despite this, drug discovery from these microorganisms has fallen out of favour due to the continual rediscovery of known compounds. To increase the chance of discovering novel antibiotics, biodiverse and rare strains should be prioritised. Subsequently, active samples need to be dereplicated as early as possible to focus efforts on truly novel compounds. In this study, 42 South African filamentous actinobacteria were screened for antimycobacterial activity using the agar overlay method against the Mtb indicator under six different nutrient growth conditions. Known compounds were subsequently identified through extraction and high-resolution mass spectrometric analysis of the zones of growth inhibition produced by active strains. This allowed the dereplication of 15 hits from six strains that were found to be producing puromycin, actinomycin D and valinomycin. The remaining active strains were grown in liquid cultures, extracted and submitted for screening against Mtb . B60 was the most active sample and was selected for bioassay-guided purification. This resulted in the identification of tetromadurin, a known compound, but which we show for the first time to have potent antitubercular activity, with the MICs within the range of 73.7-151.6 nM against H37Rv under different test conditions. This shows that South African actinobacteria are a good source of novel antitubercular compounds and warrant further screening. It is also revealed that active hits can be dereplicated by HPLC-MS/MS analysis of the zones of growth inhibition produced by the agar overlay technique.
新型抗结核化合物是对抗耐药结核分枝杆菌(Mtb)的迫切需要。丝状放线菌历来是抗结核药物的重要来源。尽管如此,由于不断重新发现已知化合物,这些微生物的药物发现已经失宠。为了增加发现新型抗生素的机会,应优先考虑生物多样性和稀有菌株。随后,应尽早对活性样品进行去重复处理,以便将精力集中在真正的新型化合物上。在这项研究中,使用琼脂覆盖法,在六种不同的营养生长条件下,对 42 株南非丝状放线菌进行了抗分枝杆菌活性筛选,以 Mtb 指示物为目标。随后通过对产生生长抑制区域的活性菌株进行提取和高分辨率质谱分析,鉴定出已知化合物。这使得从产生嘌呤霉素、放线菌素 D 和缬氨霉素的 6 株菌株中去重复了 15 个化合物。其余的活性菌株在液体培养物中生长、提取并提交给 Mtb 筛选。B60 是最活跃的样本,并被选中进行基于生物测定的纯化。这导致了 tetromadurin 的鉴定,这是一种已知的化合物,但我们首次证明它具有很强的抗结核活性,在不同的测试条件下,对 H37Rv 的 MIC 值在 73.7-151.6 nM 范围内。这表明南非放线菌是新型抗结核化合物的良好来源,值得进一步筛选。研究还揭示了通过琼脂覆盖技术产生的生长抑制区域的 HPLC-MS/MS 分析,可以对活性命中物进行去重复处理。